Fosun Pharma launches 1 billion Hong Kong dollar H share buyback

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, announced on September 7, 2026, a H-share buyback plan encompassing up to HK$1 billion. The repurchased shares will be nullified or retained as treasury shares. The company's move aims to reassure market participants of its intrinsic value and commitment to returning capital to shareholders.

The repurchase program is set to commence promptly and will be executed on an ongoing basis, adapting to prevailing market circumstances. This strategy aligns with Fosun Pharma's broader long-term value management strategy. In the first half of 2026, the company's financial health showed positive trends, with revenue from innovative drugs and international markets growing, and earnings quality enhancing year-over-year.

The repurchase funds will primarily stem from the sale of roughly 6% of Fosun Pharma's stake in Gland Pharma, generating around US$294 million in proceeds. Consequently, Fosun Pharma will maintain a 45.76% equity stake in Gland Pharma, which will continue to be consolidated within Fosun Pharma's financial statements. The acquired funds will be mainly channeled towards R&D, further share repurchases, and settling interest-bearing debts.

Despite its controlling position in Gland Pharma, Fosun Pharma remains resolute in Gland Pharma's long-term prospects and its pivotal role in overseas value generation. As the company advances, Fosun Pharma will intensify its focus on innovation and globalization, hastening the development and commercialization of its principal pipeline drugs. The share buyback reflects the company's unwavering confidence in its intrinsic value, thereby promising enduring returns for shareholders.